Multiple Myeloma

The CAR T-cell therapy PHE885 produced responses and high minimal residual disease negativity rates with no new safety signals in patients with relapsed/refractory multiple myeloma.

Teclistamab-cqyv in combination with talquetamab showcased early signs of activity with acceptable safety in patients with relapsed/refractory multiple myeloma, according to final results from the phase 1b RedirecTT-1 study.

Adam D. Cohen, MD, discusses unmet needs and areas for future investigation within the relapsed/refractory multiple myeloma treatment landscape.

Jeffery Zonder, MD, leader, multiple myeloma sub-committee, Barbara Ann Karmanos Cancer Institute, professor of medicine, Departments of Hematology and Oncology, Wayne State University School of Medicine, discusses ongoing research in multiple myeloma taking place at the Barbara Ann Karmanos Cancer Institute.

Natalie S. Callander, MD, discusses several ongoing and planned clinical trials evaluating the use of novel therapeutic regimens in multiple myeloma.

Susan Bal, MD, discusses the data that supported the FDA approvals of ide-cel and cilta-cel, how the implementation of these agents has shifted how patients with later-line relapsed/refractory multiple myeloma are treated, and the challenges that still need to be addressed with CAR T-cell therapy.

Jeffery Zonder, MD, discusses the real-world use of ixazomib-based therapy for patients with relapsed/refractory multiple myeloma as seen in the INSURE study.

Susan Bal, MD, discusses the clinical implications for the use of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Michael J. Fallon, MD, discusses guidelines for the use and administration of infection prophylaxis in relapsed/refractory multiple myeloma, as well as the future role of prophylactic immunization in this landscape.

Andrew Kin, MD, discusses clinical implications of the FDA approval for teclistamab-cqyv in relapsed/refractory multiple myeloma.

Marilena Tauro, PhD, discusses next steps planned for the development of novel autophagy inhibitory strategies to combat chemotherapy resistance in relapsed/refractory multiple myeloma.

Faculty from an OncLive® Institutional Perspectives in Cancer webinar on multiple myeloma summarize the main messages from their presentations.

For the 11th consecutive year, OncLive is honored to recognize oncology leaders whose innovations have contributed to immeasurable improvements in outcomes for countless patients.

Meera Mohan, MD, MS, FACP, discusses the significance of CAR T-cell therapies and bispecific antibodies in patients with relapsed/refractory multiple myeloma.

Susan Bal, MD, assistant professor, University of Alabama at Birmingham, discusses key efficacy and safety data from the phase 2 KarMMa trial in patients with relapsed/refractory multiple myeloma.

Attaya Suvannasankha, MD, discusses addressing the incidence of cytokine release syndrome in a first-in-human phase 1/2 trial for patients with relaped/refractory multiple myeloma.

Susan Bal, MD, discusses unmet needs with CAR T-cell therapy in multiple myeloma.

Jeffery Zonder, MD, discusses the management of toxicities associated with bispecific antibodies in patients with multiple myeloma.

Meera Mohan, MD, MS, FACP, discusses adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.

Abhinav Deol, MD, gives insight on CAR T-cell therapy’s future role in the treatment landscape for multiple myeloma and what needs to be done to push the needle forward.

Attaya Suvannasankha, MD, discusses the unique mechanism of action of REGN5459, the early efficacy and safety of the immunotherapy in heavily pretreated patients with relapsed/refractory multiple myeloma, and opportunities for further exploration.

Susan Bal, MD, discusses the evolution of CAR T-cell therapy in multiple myeloma.

Meera Mohan, MD, MS, FACP, discusses the toxicities associated with T-cell–directed therapies in relapsed/refractory multiple myeloma.

Attaya Suvannasankha, MD, discusses future research directions with bispecific antibodies in patients with multiple myeloma and potential methods for mitigating adverse effects in this population.

Marilena Tauro, PhD, discusses the role for ULK3 in regulating autophagy in multiple myeloma.

Leaked data from an abstract scheduled to be presented at the 2023 EHA Hybrid Congress showed that ciltacabtagene autoleucel demonstrated a 74% reduction in the risk of disease progression or death compared with standard therapy in patients with relapsed/refractory multiple myeloma who received 1 to 3 prior lines of therapy.

Attaya Suvannasankha, MD, discusses the safety and efficacy of REGN5459, a BCMAxCD3 bispecific antibody with low affinity to CD3 on T cells, in relapsed/refractory multiple myeloma.

The BCMA- and CD3-directed bispecific antibody REGN5459 led to fast onset, deep, and dose-dependent responses sustained over time, with a high frequency of manageable low-grade cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

The FDA has accepted a supplemental biologics license application seeking the approval of idecabtagene vicleucel for the treatment of adult patients with relapsed and refractory multiple myeloma who have received an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.

The FDA has granted an orphan drug designation to OM-301 for the treatment of patients with multiple myeloma.